Allogene Therapeutics Inc (ALLO)

Mar 04, 2026

Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat

Mar 04, 2026

Mar 03, 2026

Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance

Mar 03, 2026

Mar 03, 2026

ALLO: Key clinical milestones and manufacturing advances position allogeneic cell therapy for broad impact - TradingView

Mar 03, 2026

Mar 02, 2026

Allogene Therapeutics (NASDAQ: ALLO) files Form 144 for 7,132 RSU shares - Stock Titan

Mar 02, 2026

Mar 02, 2026

Allogene Therapeutics signals breakthrough hope for severe autoimmune disease patients - Traders Union

Mar 02, 2026

Mar 02, 2026

Cancer CAR T firm Allogene sets March 12 call on 2025 results - Stock Titan

Mar 02, 2026

Mar 02, 2026

Ideas Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Mar 02, 2026

Mar 01, 2026

ALLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 01, 2026

Feb 28, 2026

Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat

Feb 28, 2026

Feb 27, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Feb 27, 2026

Feb 25, 2026

Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year HighHere's What Happened - MarketBeat

Feb 25, 2026

Feb 25, 2026

FOMO Trade: Is Allogene Therapeutics Inc.’s ROE strong enoughGold Moves & Weekly Breakout Watchlists - mfd.ru

Feb 25, 2026

Feb 24, 2026

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%Should You Buy? - MarketBeat

Feb 24, 2026

Feb 23, 2026

Allogene Therapeutics2026 Funding Rounds & List of Investors - Tracxn

Feb 23, 2026

Feb 22, 2026

Allogene Therapeutics (NASDAQ:ALLO) Raised to "Hold" at Wall Street Zen - MarketBeat

Feb 22, 2026

Feb 19, 2026

Treasury Yields: Whats the fair value of Blend Labs Inc stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Feb 19, 2026

Feb 19, 2026

Allogene Therapeutics Faces Financial Challenges Despite Industry Moves - StocksToTrade

Feb 19, 2026

Feb 18, 2026

Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission - Yahoo Finance

Feb 18, 2026

Feb 18, 2026

MSN Money - MSN

Feb 18, 2026

Feb 18, 2026

ALLO: ALPHA-3 aims for a 25%-30% MRD clearance improvement in lymphoma, with pivotal data due in April - TradingView

Feb 18, 2026

Feb 17, 2026

Arie Belldegrun details 5.8% Allogene (ALLO) stake via multiple entities - Stock Titan

Feb 17, 2026

Feb 16, 2026

Allogene Therapeutics unveils plans for Virtual Oncology Summit - Traders Union

Feb 16, 2026

Feb 16, 2026

Atomera Among 3 Promising Penny Stocks - simplywall.st

Feb 16, 2026

Feb 15, 2026

Will Allogene Therapeutics Inc. stock outperform value stocks2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru

Feb 15, 2026

Feb 14, 2026

Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen - MarketBeat

Feb 14, 2026

Feb 13, 2026

Will Allogene Therapeutics Inc. benefit from geopolitical trendsQuarterly Portfolio Report & Fast Entry Momentum Alerts - mfd.ru

Feb 13, 2026

Feb 13, 2026

ALLO PE Ratio & Valuation, Is ALLO Overvalued - Intellectia AI

Feb 13, 2026

Feb 13, 2026

Follicular Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic - Barchart.com

Feb 13, 2026

Feb 13, 2026

Aug Selloffs: Is Bank of Montreal on track to beat earningsPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn

Feb 13, 2026

Feb 13, 2026

Dr. Chang (NASDAQ: ALLO) discloses 5.2% Allogene ownership stake - Stock Titan

Feb 13, 2026

Feb 11, 2026

Will Allogene Therapeutics Inc. outperform small cap indexesEarnings Trend Report & AI Powered Trade Plan Recommendations - mfd.ru

Feb 11, 2026

Feb 11, 2026

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance

Feb 11, 2026

Feb 10, 2026

Why Allogene Therapeutics Inc. stock could see breakout soonTreasury Yields & Stock Portfolio Risk Management - mfd.ru

Feb 10, 2026

Feb 09, 2026

Aug Drivers: Will Allogene Therapeutics Inc stock hit new highs in YEAREarnings Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn

Feb 09, 2026

Feb 07, 2026

Allogene Therapeutics Approaches a Defining Period for Its Platform - AD HOC NEWS

Feb 07, 2026

Feb 06, 2026

Don't Ignore The Insider Selling In Allogene Therapeutics - 富途牛牛

Feb 06, 2026

Feb 05, 2026

Allogene Therapeutics explores cell therapy trial at ASTCT meeting - Traders Union

Feb 05, 2026

Feb 05, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewswire

Feb 05, 2026

Feb 05, 2026

Allogene EVP Roberts sells $63,189 in stock, gains options By Investing.com - Investing.com Canada

Feb 05, 2026

Feb 05, 2026

Allogene Therapeutics CEO Chang David D sells $171k in stock - Investing.com Canada

Feb 05, 2026

Feb 04, 2026

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics SVP sells $13k in stock By Investing.com - Investing.com South Africa

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics (NASDAQ:ALLO) EVP Sells $63,189.00 in Stock - MarketBeat

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics (NASDAQ:ALLO) CEO David Chang Sells 95,269 Shares - MarketBeat

Feb 04, 2026

Feb 04, 2026

Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,549 Shares of Stock - MarketBeat

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics (NASDAQ:ALLO) CFO Sells $42,241.76 in Stock - MarketBeat

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics (ALLO) Is Up 24.1% After Extended Cash Runway and CAR T Trial Progress - Yahoo Finance

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics SVP sells $13k in stock - Investing.com Nigeria

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics SVP sells $40k in stock By Investing.com - Investing.com Canada

Feb 04, 2026

Feb 04, 2026

Allogene Therapeutics SVP sells $40k in stock - Investing.com

Feb 04, 2026